Circulating levels of proprotein convertase subtilisin kexin type 9 are elevated by fibrate therapy: A systematic review and meta-analysis of clinical trials

Cardiology in Review

Volumn 22, Issue 6, 2014, Pages 306-312

  Sahebkar, Amirhossein ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cholesterol; Dyslipidemia; Fibric acid; Peroxisome proliferator activated receptor alpha; Proprotein convertase subtilisin kexin type 9

Indexed keywords

BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

DATA SYNTHESIS; ENZYME ASSAY; ENZYME BLOOD LEVEL; HUMAN; META ANALYSIS; PUBLISHING; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; AGED; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DYSLIPIDEMIAS; FEMALE; MALE; METABOLISM; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; FIBRIC ACIDS; HUMANS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERINE ENDOPEPTIDASES;

EID: 84927690991     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0000000000000025     Document Type: Review

References (53)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-1389.
2. Sacks FM, Pfeffer MA, Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335:1001-1009.
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339:1349-1357.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360:7-22.
5. Schwartz GG, Olsson AG, Ezekowitz M.D., et al.; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285:1711-1718.
6. Murphy SA, Cannon C P, Wiviott SD, et al. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009; 54:2358-2362.
7. Mills EJ, Rachlis B, Wu P., et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008; 52:1769-1781.
8. Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012; 14:1-10.
9. Ya n AT, Ya n RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006; 119:676-683.
10. Joy TR. Novel therapeutic agents for lowering low density lipoprotein cholesterol. Pharmacol Ther. 2012; 135:31-43.
11. Li H, Li H, Ziegler N., Cui R, Liu J. Recent patents on PCSK9: a new target for treating hypercholesterolemia. Recent Pat DNA Gene Seq. 2009; 3:201-212.
12. Marian AJ. PCSK9 as a therapeutic target in atherosclerosis. Curr Atheroscler Rep. 2010; 12:151-154.
13. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A. 2005; 102:2069-2074.
14. Seidah NG, Benjannet S, Wickham L., et al. The secretory proprotein conver-tase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003; 100:928-933.
15. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A. 2005; 102:2069-2074.
16. Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A. 2005; 102:5374-5379.
17. Abifadel M, Varret M, Rabès J P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34:154-156.
18. Fasano T, Cefalù AB, Di Leo E, et al. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol. 2007; 27:677-681.
19. Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis. 2011; 216:258-265.
20. Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013; 35:1082-1098.
21. Sahebkar A, Watts GF. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther. 2013:27:559-67.
22. Weinreich M, Frishman WH. Antihyperlipidemic therapies targeting PCSK9. Cardiol Rev. 2014; 22:140-146.
23. Konrad RJ, Troutt JS, Cao G. Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis. 2011; 10:38.
24. Costet P, Hoffmann MM, Cariou B, et al. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis. 2010; 212:246-251.
25. Welder G, Zineh I, Pacanowski M.A., et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 2010; 51:2714-2721.
26. Careskey HE, Davis RA, Alborn W.E., et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res. 2008; 49:394-398.
27. Dubuc G, Chamberland A, Wassef H., et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated conver-tase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004; 24:1454-1459.
28. Noguchi T, Kobayashi J, Yagi K., et al. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study. Atherosclerosis. 2011; 217:165-170.
29. Troutt JS, Alborn WE, Cao G, Konrad RJ. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res. 2010; 51:345-351.
30. Mayne J, Dewpura T, Raymond A., et al. Plasma PCSK9 levels are sig-nificantly modified by statins and fibrates in humans. Lipids Health Dis. 2008; 7:22.
31. Chan DC, Hamilton SJ, Rye K.A., et al. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. Diabetes Obes Metab. 2010; 12:752-756.
32. Lambert G, Ancellin N, Charlton F., et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem. 2008; 54:1038-1045.
33. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions Version 5.0.2. The Cochrane Collboration; 2009.
34. Borenstein M, Hedges L, Higgins J., Rothstein H. Comprehensive Meta-analysis Version 2. Englewood, NJ: Biostat; 2005.
35. Hashimoto F, Taira S, Hayashi H. Changes in isoprenoid lipid synthesis by gemfibrozil and clofibric acid in rat hepatocytes. Biochem Pharmacol. 2000; 59:1203-1210.
36. Guo Q, Wang PR, Milot D P, et al. Regulation of lipid metabolism and gene expression by fenofibrate in hamsters. Biochim Biophys Acta. 2001; 1533:220-232.
37. Qin W, Infante J, Wang S.R., et al. Regulation of HMG-CoA reductase, apopro-tein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes. Biochim Biophys Acta. 1992; 1127:57-66.
38. Keating GM, Croom KF. Fenofibrate: a review of its use in primary dys-lipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007; 67:121-153.
39. Valasek MA, Clarke SL, Repa JJ. Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. J Lipid Res. 2007; 48:2725-2735.
40. Martens K, Ver Loren van Themaat E, van Batenburg MF, et al. Coordinate induction of PPAR alpha and SREBP2 in multifunctional protein 2 deficient mice. Biochim Biophys Acta. 2008; 1781:694-702.
41. Maxwell KN, Soccio RE, Duncan E.M., et al. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterolfied mice. J Lipid Res. 2003; 44:2109-2119.
42. Costet P, Cariou B, Lambert G., et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem. 2006; 281:6211-6218.
43. Elkeles R. Fibrates: old drugs with a new role in type 2 diabetes prevention? Br J Diabetes Vasc Dis. 2011; 11:4-9.
44. Kourimate S, Le May C, Langhi C, et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem. 2008; 283:9666-9673.
45. Palmer CN, Hsu MH, Griffin K.J., et al. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol. 1998; 53: 14-22.
46. Chan DC. Regulation of proprotein convertase subtilisin/kexin type 9: therapeutical perspectives. Atherosclerosis. 2011; 217:77-79.
47. Baass A, Dubuc G, Tremblay M., et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem. 2009; 55:1637-1645.
48. Sahebkar A, Watts GF. Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Atherosclerosis. 2013; 230:110-120.
49. Lakoski SG, Lagace TA, Cohen J.C., et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009; 94: 2537-2543.
50. Niesen M, Bedi M, Lopez D. Diabetes alters LDL receptor and PCSK9 expression in rat liver. Arch Biochem Biophys. 2008; 470:111-115.
51. Vergès B, Duvillard L, Brindisi M.C., et al. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes. Atherosclerosis. 2011; 219:342-348.
52. Kappelle PJ, Lambert G, Dullaart R P. Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients. Atherosclerosis. 2011; 214:432-435.
53. Brouwers MC, Troutt JS, van Greevenbroek MM, et al. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study. Atherosclerosis. 2011; 217:263-267.